TABLE 1 

Baseline characteristics of the study population

Data are presented as mean (S.D.) unless indicated as n (%). BMI was calculated as weight in kilograms divided by height in meters squared. NAFLD activity score was assessed on a scale of 0–8, with higher scores showing more severe disease; the components of this measure were steatosis (assessed on a scale of 0–3), lobular inflammation (assessed on a scale of 0–3), and hepatocellular ballooning (assessed on a scale of 0–2). Portal inflammation was assessed on a scale of 0–2, with higher scores showing more severe inflammation. Mean fibrosis stage was assessed on a scale of 0–4, with higher scores showing more severe fibrosis.

CharacteristicsHealthySteatosisNASH
Age, y19.3 (1.2)15.3 (2.3)17.4 (1.7)
Female sex, n (%)8 (47.1)5 (71.4)2 (40)
Hispanic ethnicity, n (%)3 (17.6)7 (100)5 (100)
Race, n (%)
 Asian or Pacific Islander5 (29.4)00
 Caucasian10 (58.8)00
 ≥2 Races01 (14.3)0
Height, cm170.3 (11.0)163.5 (10.2)166.5 (11.6)
Weight, kg69.3 (15.4)89.6 (24.4)107.2 (22.5)
BMI, kg/m223.8 (4.8)33.1 (5.3)38.3 (3.3)
ALT, U/L18 (6)79 (70)73 (37)
Liver histology
 NAFLD activity score (NAS)NA4.0 (1.4)5.6 (0.5)
 Steatosis scoreNA2.1 (0.7)2.2 (0.8)
 Lobular inflammation scoreNA1.4 (0.8)2.0 (0.0)
 Portal inflammation scoreNA0.6 (0.5)0.6 (0.5)
 Hepatocellular ballooning scoreNA0.4 (0.5)1.6 (0.9)
 Fibrosis stageNA1 (1.7)2 (2.3)
CYP polymorphisms, n (%)
 CYP2C9*24 (23.5)01 (20)
 CYP2C9*34 (23.5)1 (14.3)0
 CYP2C19*24 (23.5)1 (14.3)0
 CYP2C19*174 (23.5)01 (20)
 CYP3A4*1b3 (17.6)3 (42.9)1 (20)
 CYP3A5*35 (29.4)4 (57.1)1 (20)
  • NA, not applicable.